Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | FHIT | P49789 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17298713 | 0.72 | — | — | |
| SCHEMBL17288435 | 0.70 | — | — | |
| SCHEMBL3151430 | 0.68 | CA1 (0.49) | MPIGAAMAPK1CYP1A2CA1 | |
| SCHEMBL2616845 | 0.67 | TARBP2 (0.43) | GAAHPGDHSD17B10RAB9AKDM4E | |
| SCHEMBL13154848 | 0.66 | NUDT1 (0.42) | CYP1A2CA1CA2TSHRHDAC4 | |
| SCHEMBL11423465 | 0.66 | CA1 (0.47) | MPIGAAHPGDHSD17B10KDM4E | |
| SCHEMBL3823734 | 0.66 | CA1 (0.50) | MPIGAAHPGDHSD17B10KDM4E | |
| SCHEMBL3575403 | 0.66 | HTT (0.38) | GAAHPGDKDM4EMAPK1ALDH1A1 | |
| SCHEMBL529605 | 0.66 | CA1 (0.50) | MPIGAAHPGDHSD17B10RAB9A | |
| SCHEMBL16000888 | 0.66 | CA1 (0.47) | MPIGAAHPGDHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002497-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2025-01-02 | — | — | US | disclosed |
| CN-108383858-B | Derivatives of imidazothiadiazoles and imidazopyrazines for the treatment of platelet aggregation | 百时美施贵宝公司 | 2024-09-20 | — | — | CN | disclosed |
| US-12084452-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| EP-3632919-B1 | PHARMACEUTICAL COMPOISITIONS COMPRISING IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2022-10-26 | — | — | EP | disclosed |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-03 | — | — | US | disclosed |
| WO-2020117974-A1 | COMPOUNDS AND COMPOSITIONS FOR EYE TREATMENTS | AVEDRO, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2020-04-23 | — | — | US | disclosed |
| EP-3632919-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3243826-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20090131489-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | KUO GEE-HONG | 2009-05-21 | — | — | US | disclosed |
| US-20090131489-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | KUO GEE-HONG | 2009-05-21 | — | — | US | disclosed |
| WO-2009037485-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2009-03-26 | — | — | WO | disclosed |
| US-7498351-B2 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-03 | — | — | US | disclosed |
| EP-1684752-B1 | PHENOXYACETIC ACIDS DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DUAL AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2007-05-16 | — | — | EP | disclosed |
| EP-1684752-A1 | PHENOXYACETIC ACIDS DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DUAL AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-02 | — | — | EP | disclosed |
| US-7015329-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N. V. (BE) | 2006-03-21 | — | — | US | disclosed |
| WO-2005041959-A1 | PHENOXYACETIC ACIDS DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DUAL AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096362-A1 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-05 | — | — | US | disclosed |
| US-4115095-A | FOR REDUCTION OF HERBICIDAL INJURY TO DESIRABLE PLANTS | MONSANTO COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, TMPRSS4, F2R | MPI 1593/4885GAA 4106/4885HPGD 1417/4885 |
| US-20050096362-A1 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | MPI 2668/4885GAA 833/4885HPGD 2846/4885 |
| US-20090131489-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | MPI 2668/4885GAA 833/4885HPGD 2846/4885 |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | MPI 1552/4885GAA 4086/4885HPGD 1365/4885 |
| US-12084452-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, F2R, TMPRSS4 | MPI 1552/4885GAA 4086/4885HPGD 1365/4885 |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | MPI 1593/4885GAA 4106/4885HPGD 1417/4885 |
| US-20250002497-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | MPI 1602/4885GAA 4038/4885HPGD 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.